BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 26551023)

  • 1. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ayele HT; Mourik MS; Debray TP; Bonten MJ
    PLoS One; 2015; 10(11):e0142290. PubMed ID: 26551023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
    Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
    BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of latent tuberculosis infection in HIV infected persons.
    Akolo C; Adetifa I; Shepperd S; Volmink J
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD000171. PubMed ID: 20091503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid for preventing tuberculosis in HIV-infected children.
    Zunza M; Gray DM; Young T; Cotton M; Zar HJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD006418. PubMed ID: 28850172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of latent tuberculosis infection in HIV infected persons.
    Woldehanna S; Volmink J
    Cochrane Database Syst Rev; 2004; (1):CD000171. PubMed ID: 14973947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control.
    Churchyard GJ; Chaisson RE; Maartens G; Getahun H
    S Afr Med J; 2014 Apr; 104(5):339-43. PubMed ID: 25212199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children.
    Gray DM; Zar H; Cotton M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006418. PubMed ID: 19160285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
    Semu M; Fenta TG; Medhin G; Assefa D
    BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
    Assebe LF; Reda HL; Wubeneh AD; Lerebo WT; Lambert SM
    BMC Public Health; 2015 Apr; 15():346. PubMed ID: 25886730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.
    Briggs MA; Emerson C; Modi S; Taylor NK; Date A
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S297-305. PubMed ID: 25768869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary isoniazid preventive therapy : A strategy still relevant in the era of test and treat ; literature review].
    Moh DR; Badjé A; Kassi AN; Ntakpé JB; Kouame GM; Ouassa T; Danel C; Domoua SK; Anglaret X; Eholié SP
    Rev Epidemiol Sante Publique; 2022 Nov; 70(6):305-313. PubMed ID: 36307330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
    Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
    Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
    Durovni B; Cavalcante SC; Saraceni V; Vellozo V; Israel G; King BS; Cohn S; Efron A; Pacheco AG; Moulton LH; Chaisson RE; Golub JE
    AIDS; 2010 Nov; 24 Suppl 5(Suppl 5):S49-56. PubMed ID: 21079428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.
    Mills HL; Cohen T; Colijn C
    J R Soc Interface; 2011 Oct; 8(63):1510-20. PubMed ID: 21508012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.
    Huerga H; Mueller Y; Ferlazzo G; Mpala Q; Bevilacqua P; Vasquez B; Noël Mekiedje C; Ouattara A; Mchunu G; Weyenga HO; Varaine F; Bonnet M
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):e89-95. PubMed ID: 26910386
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.